Mizuho Reiterates Buy on Axsome Therapeutics, Maintains $95 Price Target
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Graig Suvannavejh reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a $95 price target.
June 12, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh reiterated a Buy rating on Axsome Therapeutics and maintained a $95 price target.
The Buy rating and maintained $95 price target by Mizuho analyst Graig Suvannavejh on Axsome Therapeutics (NASDAQ:AXSM) indicates a positive outlook for the stock. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100